Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NASDAQ:GTHX NASDAQ:PRVB NASDAQ:VNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$35.30-0.7%$36.08$23.23▼$39.95$1.11B0.65330,173 shs181,801 shsGTHXG1 Therapeutics$7.15$7.13$1.08▼$7.19$373.81M1.661.70 million shsN/APRVBProvention Bio$24.98$24.58$3.18▼$25.00$2.37B2.472.28 million shs218,200 shsVNDAVanda Pharmaceuticals$5.50+0.2%$4.90$3.81▼$5.62$324.40M0.74573,210 shs514,904 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical-0.68%+4.01%+0.40%+11.08%-1.64%GTHXG1 Therapeutics0.00%0.00%0.00%0.00%0.00%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%VNDAVanda Pharmaceuticals+0.18%+4.36%+12.24%+16.03%+17.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$35.30-0.7%$36.08$23.23▼$39.95$1.11B0.65330,173 shs181,801 shsGTHXG1 Therapeutics$7.15$7.13$1.08▼$7.19$373.81M1.661.70 million shsN/APRVBProvention Bio$24.98$24.58$3.18▼$25.00$2.37B2.472.28 million shs218,200 shsVNDAVanda Pharmaceuticals$5.50+0.2%$4.90$3.81▼$5.62$324.40M0.74573,210 shs514,904 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical-0.68%+4.01%+0.40%+11.08%-1.64%GTHXG1 Therapeutics0.00%0.00%0.00%0.00%0.00%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%VNDAVanda Pharmaceuticals+0.18%+4.36%+12.24%+16.03%+17.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.60Moderate Buy$42.3319.92% UpsideGTHXG1 Therapeutics 0.00N/AN/AN/APRVBProvention Bio 0.00N/AN/AN/AVNDAVanda Pharmaceuticals 2.67Moderate Buy$16.50200.00% UpsideCurrent Analyst Ratings BreakdownLatest GTHX, COLL, PRVB, and VNDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025COLLCollegium PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/24/2025VNDAVanda PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/23/2025COLLCollegium PharmaceuticalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/8/2025COLLCollegium PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025VNDAVanda PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025COLLCollegium PharmaceuticalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025VNDAVanda PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/24/2025COLLCollegium PharmaceuticalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/21/2025VNDAVanda PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/11/2025COLLCollegium PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$44.00(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$707.01M1.57$12.26 per share2.88$7.10 per share4.97GTHXG1 Therapeutics$58.20M6.42N/AN/A$0.68 per share10.51PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84VNDAVanda Pharmaceuticals$198.77M1.64N/AN/A$9.24 per share0.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$69.19M$1.0433.945.86N/A5.13%97.28%13.87%11/6/2025 (Estimated)GTHXG1 Therapeutics-$47.97M-$0.62N/AN/AN/A-76.93%-136.98%-39.33%N/APRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/AVNDAVanda Pharmaceuticals-$18.90M-$1.13N/AN/AN/A-32.90%-12.89%-10.47%10/29/2025 (Estimated)Latest GTHX, COLL, PRVB, and VNDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025COLLCollegium Pharmaceutical$1.89N/AN/AN/A$191.25 millionN/A10/29/2025Q3 2025VNDAVanda Pharmaceuticals-$0.38N/AN/AN/A$58.73 millionN/A7/31/2025Q2 2025VNDAVanda Pharmaceuticals-$0.34-$0.46-$0.12-$0.46$54.77 million$52.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical3.271.181.10GTHXG1 Therapeutics1.342.482.12PRVBProvention Bio0.191.931.92VNDAVanda PharmaceuticalsN/A3.253.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AGTHXG1 Therapeutics24.21%PRVBProvention Bio37.39%VNDAVanda Pharmaceuticals88.14%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical2.51%GTHXG1 Therapeutics6.11%PRVBProvention Bio13.10%VNDAVanda Pharmaceuticals10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21031.50 million30.71 millionOptionableGTHXG1 Therapeutics17052.28 million49.09 millionOptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableVNDAVanda Pharmaceuticals29059.09 million53.18 millionOptionableGTHX, COLL, PRVB, and VNDA HeadlinesRecent News About These CompaniesVanda Pharmaceuticals (VNDA) to Release Quarterly Earnings on WednesdayOctober 24 at 4:22 PM | marketbeat.comVanda Pharmaceuticals (NASDAQ:VNDA) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?October 24 at 3:56 AM | marketbeat.comVanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025October 22 at 4:30 PM | prnewswire.comVanda Pharmaceuticals (NASDAQ:VNDA) Stock Price Crosses Above 200 Day Moving Average - What's Next?October 16, 2025 | marketbeat.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)October 9, 2025 | marketbeat.comMonumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown ArenaOctober 8, 2025 | prnewswire.comVanda Pharmaceuticals, FDA agree to resolve disputes on Hetlioz and tradipitantOctober 1, 2025 | msn.comVanda Pharmaceuticals Reaches Agreement with FDAOctober 1, 2025 | tipranks.comVanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug AdministrationOctober 1, 2025 | prnewswire.comVanda Pharmaceuticals’ Hetlioz meets primary endpoints in insomnia studySeptember 25, 2025 | msn.comVanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"September 25, 2025 | prnewswire.comVanda: Next Phase Of Fanapt Growth Might Be With Bysanti AdvancementAugust 29, 2025 | seekingalpha.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia ...August 29, 2025 | finanznachrichten.deVanda Pharmaceuticals Announces Participation at September 2025 Investor ConferencesAugust 28, 2025 | prnewswire.comVanda Pharmaceuticals gets FDA orphan drug status for VGT-1849BAugust 28, 2025 | seekingalpha.comVanda Pharmaceuticals stock rises after FDA orphan drug designationAugust 28, 2025 | za.investing.comVanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia VeraAugust 28, 2025 | prnewswire.comVanda Pharmaceuticals treatment of polycythemia vera granted orphan designationAugust 27, 2025 | msn.comVanda seeks FDA Commissioner review of Hetlioz generic rulingAugust 22, 2025 | msn.comVanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®August 21, 2025 | prnewswire.comVanda wins appeals court fight over FDA jet lag rulingAugust 19, 2025 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Bassett Furniture: Buy Now, Sit Back, and Collect DividendsBy Thomas Hughes | October 11, 2025GTHX, COLL, PRVB, and VNDA Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$35.30 -0.24 (-0.68%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$35.30 +0.01 (+0.01%) As of 10/24/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.G1 Therapeutics NASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Provention Bio NASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Vanda Pharmaceuticals NASDAQ:VNDA$5.50 +0.01 (+0.18%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$5.57 +0.07 (+1.27%) As of 10/24/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
